Schonfeld Strategic Advisors’s BioTelemetry, Inc. BEAT Stock Holding History

Schonfeld Strategic Advisors’s Portfolio BEAT Stock Details BEAT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q1	–	Sell	-17,512	Closed	-$1.26M	–	2381
2020 Q4	$1.26M	Buy	+17,512	New	+$917K	0.02%	730
2019 Q3	–	Sell	-4,380	Closed	-$211K	–	1365
2019 Q2	$211K	Buy	4,380 +980	+29%	+$51.5K	0.01%	880
2019 Q1	$213K	Buy	+3,400	New	+$234K	0.01%	931
2017 Q3	–	Sell	-35,000	Closed	-$1.17M	–	874
2017 Q2	$1.17M	Sell	35,000 -741	-2%	-$22.1K	0.12%	242
2017 Q1	$1.03M	Buy	+35,741	New	+$885K	0.1%	254

Other funds holding BEAT

LCM

Logan Capital Management Newtown Square, Pennsylvania $2.3B AUM 30.85% 1-Year Est. Return

Schonfeld Strategic Advisors's BEAT Position: Q1 2021 in Review

Schonfeld Strategic Advisors sold out of BioTelemetry, Inc. (BEAT) in Q1 2021, closing a stake of 17,512 shares — an estimated $1.26M sold.

Schonfeld Strategic Advisors first reported a position in BEAT in Q1 2017 and held it in 5 quarters. The position peaked at $1.26M in Q4 2020. 1 fund tracked by Wall St. Rank holds BEAT as of Q1 2021.

Schonfeld Strategic Advisors reported no remaining BioTelemetry, Inc. position as of Q1 2021 after selling out during the quarter.
Schonfeld Strategic Advisors sold 17,512 BioTelemetry, Inc. shares in Q1 2021, an estimated $1.26M.
Schonfeld Strategic Advisors first reported a position in BioTelemetry, Inc. in Q1 2017 and held it in 5 quarters.
Schonfeld Strategic Advisors's BioTelemetry, Inc. position peaked at $1.26M in Q4 2020.
1 fund tracked by Wall St. Rank held BioTelemetry, Inc. as of Q1 2021.

Based on Schonfeld Strategic Advisors's 13F filing for Q1 2021, filed 17 May 2021.